Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 85

Results For "CE"

7512 News Found

Caplin Group commences operations of Rs. 150 crore oncology facility
News | March 28, 2024

Caplin Group commences operations of Rs. 150 crore oncology facility

The facility will manufacture tablets, capsules, and injections for the oncology segment


EC approves Merck’s Keytruda plus chemotherapy as neoadjuvant treatment for non-small cell lung cancer
Drug Approval | March 28, 2024

EC approves Merck’s Keytruda plus chemotherapy as neoadjuvant treatment for non-small cell lung cancer

Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results


Apollo Cancer Centres heralds a new era in breast cancer surgery
Healthcare | March 27, 2024

Apollo Cancer Centres heralds a new era in breast cancer surgery

The surgeons were able to remove the entire breast while preserving the nipple through tiny hidden incisions


USFDA grants ODD to Cevidoplenib for immune thrombocytopenia
News | March 23, 2024

USFDA grants ODD to Cevidoplenib for immune thrombocytopenia

Oscotec has successfully completed phase 2 study in patients with chronic ITP last year


Dr. Reddy's and Pharmazz inks agreement to market Centhaquine for hypovolemic shock in India
Drug Approval | March 23, 2024

Dr. Reddy's and Pharmazz inks agreement to market Centhaquine for hypovolemic shock in India

Centhaquine is a resuscitative agent presently indicated for the treatment of hypovolemic shock by DGCI


AstraZeneca’s FLAURA2 Phase III trial showed favourable trend in EGFR-mutated advanced lung cancer
Diagnostic Center | March 23, 2024

AstraZeneca’s FLAURA2 Phase III trial showed favourable trend in EGFR-mutated advanced lung cancer

Combination shows consistent benefit across prespecified post-progression outcomes


Zydus receives tentative approval from USFDA for Letermovir Tablets
Drug Approval | March 23, 2024

Zydus receives tentative approval from USFDA for Letermovir Tablets

Letermovir tablets, 240 mg and 480 mg had annual sales of USD 289.5 mn in the United States (IQVIA MAT Jan-24)


Akums introduces Hydroxyurea oral suspension for sickle cell disease
Healthcare | March 22, 2024

Akums introduces Hydroxyurea oral suspension for sickle cell disease

This new medication eliminates the need for cold storage, making it more accessible and affordable for SCD patients across India


Merck invests € 300 million in new Life Science production site in South Korea
News | March 21, 2024

Merck invests € 300 million in new Life Science production site in South Korea

New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics